Meeting Room: Room 331, Level 3, Suntec Singapore | ||
Time | Programme | |
10:00 – 11:20 | HBV Cure Overview | |
Chair and Moderator : Seng Gee Lim (Singapore) | ||
10:00 – 10:10 | Opening Lecture: How to Eradicate HBV? | |
Geoffrey Dusheiko, UK | ||
10:10 – 10:20 | State of the Action: HBV Cure Strategy from HBV Foundation | |
Robert Gish, HBV Foundation | ||
10:20 – 10:40 | International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) Progress Report 2019 | |
Peter Revill, Australia | ||
10:40 – 10:55 | HBV Forum: Achievements to Date | |
Veronica Miller, USA | ||
10:55 – 11:05 | Insights for HBV Cure from HIV Cure Strategies | |
Jonathan Karn, USA | ||
11:05– 11:20 | Discussion Forum led by the Moderator | |
11:20 – 12:10 | Models for HBV Infection | |
Chair and Moderator : Atefeh Khakpoor (Singapore) | ||
11:20 – 11:35 | Novel In-Vitro Models : An Overview | |
Peter Revill, Australia | ||
11:35 – 11:50 | Humanised Mouse Models: State of the Art | |
Qingfeng Chen, Singapore | ||
11:50 – 12:10 | Discussion Forum led by the Moderator | |
12:10 – 13:00 | Lunch | |
13:00 – 14:30 | Clinical & Translational Forum | |
Chair and Moderator: Peter Revill (Australia) | ||
13:00 – 13:15 | Insights into Host Genes in HBV Clearance | |
Martin Hibberd, Singapore | ||
13:15 – 13:30 | HBV Viral Integration : Implications for a HBV Cure | |
Stephan Urban, Germany | ||
Invited Oral & Free Paper Presentations | ||
13:30 – 13:45 | Development of Novel Markers of Treatment Response | |
Gavin Cloherty, Abbott Diagnostics | ||
13:45 – 13:55 | Peginterferon Therapy in CHB Carriers, A Randomised Control Trial. Preliminary Results and Insights | |
Seng Gee Lim, Singapore | ||
13:55 – 14:05 | Understanding IFN Subtype: Harnessing the Power of IFN for HBV Cure | |
Zhenghong Yuan, China | ||
14:05 – 14:15 | HBV Surface Antigen Large And Middle Isoform Composition Do Not Correlate To Disease Stage | |
Gavin Cloherty, Abbott Laboratories | ||
14:15 – 14:30 | Discussion Forum led by the Moderator | |
14:30 – 16:25 | Viral Transcription | |
Chair and Moderator: Stephen Locarnini (Australia) | ||
14:30 – 14:45 | cccDNA Update: Where Are We in 2019? | |
Haitao Guo, USA | ||
14:45 – 15:00 | State of the Art: CRISPR-CAS9 in Human Cells | |
Tan Meng How, Singapore | ||
15:00 – 15:30 | Debate: HBV cccDNA Management | |
· It is better to eliminate cccDNA: Massimo Levrero, France | ||
· It is better to silence cccDNA: Haitao Guo, USA | ||
Invited Oral & Free Paper Presentations | ||
15:30 – 15:40 | Using a modified HBV genome and insertional chromatin immunoprecipitation to screen for cccDNA-associated nuclear factors | |
Nur Khairiah Mohd-Ismail, Singapore | ||
15:40 – 15:50 | A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model | |
Lu Gao, Roche | ||
15:50 – 16:00 | Thiazolides in the treatment of chronic HBV: Can it be a cure | |
Jean-François Rossignol, Romark, L.C | ||
16:00 – 16:25 | Discussion Forum led by the Moderator | |
16:25 – 16:40 | Tea Break | |
16:40 – 18:00 | Capsid Inhibition | |
Chair and Moderator: Jorg Peterson (Germany) | ||
16:40 – 16:55 | Mechanism and Efficacy of Capsid Inhibitors | |
Stephen Locarnini, Australia | ||
16:55 – 17:10 | Biology of HBV Core Phosphorylation and Targets | |
Pei-Jer Chen, Taiwan | ||
Invited Oral & Free Paper Presentations | ||
17:10 – 17:20 | RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients | |
Man-Fung Yuen, Hong Kong | ||
17:20 – 17:30 | Targeting a functional cure for HBV: learning from the clinical studies of the capsid assembly modulators JNJ-6379 and JNJ-0440 | |
Oliver Lenz, Janssen Pharmaceutica | ||
17:30 – 17:40 | Proteome and Phosphosproteome profiling Of Hepatitis B Virus (HBV)-Infected Cells | |
Lim Zijie, Singapore | ||
17:40 – 18:00 | Discussion Forum led by the Moderator | |
End of Day 1 | ||
| 欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |